Ann: Investor presentation , page-9

This was supposed to be in last post dont know what happened there

Philippe Archinard, Chairman and Chief Executive Officer of Transgene, said: “We are very pleased to be moving forward with the construction phase of this important new commercial production unit. Our decision to invest now reflects the increasing confidence in our programs, including our cancer immunotherapy candidate, TG4010, for which we recently announced topline preliminary data from a clinical study in non-small cell lung cancer. We are building a strong future for Transgene and are taking the steps needed to ensure sufficient future commercial supply.” Mr. Archinard continued: “Sanofi is an ideal partner with extensive experience in effectively managing large production projects and manufacturing novel therapies in commercial quantities.”